cabozantinib,atezolizumab
roche
['contact-03', 'rcc,(-irccs),(-srcc),(-urcc)', 'atezo', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'gucsm', 'cabozantinib']
#asco23: contact-03 results indicate no benefit to adding atezolizumab to cabozantinib observed in 2l treatment of mrcc: #ascodailynews #gucsm 
Account of the American Society of Clinical Oncology & its affiliate the Association for Clinical Oncology. Assoc tweets labeled #ASCOAdvocacy. RTs ≠ endorse.